RxDoctor Payments DataLook up a doctor →

Vidhyalakshmi Kannan, MD

Endocrinology, Diabetes & Metabolism · Mesa, AZNPI 1275724452

Payments from drug & device makers

$110,638in general payments, 2019–2025

Across 1,435 payments — averaging $77.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$48K
  • Boehringer Ingelheim$23K
  • Lilly USA, LLC$22K
  • Medtronic$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • plus $13K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Corcept Therapeutics141$47,622
Boehringer Ingelheim98$22,850
Lilly USA, LLC168$21,762
Medtronic(2 entities)57$1,770
AstraZeneca(2 entities)83$1,724
Novo Nordisk101$1,687
Insulet Corporation68$1,392
Xeris Pharmaceuticals, Inc.57$1,088
Sanofi-aventis U.S. LLC53$985
Mannkind Corporation70$983
Radius Health, Inc.68$888
Amgen(2 entities)49$811
Dexcom, Inc.42$742
AbbVie38$645
Antares Pharma, Inc.59$607
Bayer32$598
BETA Bionics, Inc.36$597
Abbott30$446
Amneal Pharmaceuticals LLC21$372
Recordati_rare_diseases_inc.17$322
Merck23$302
Zealand Pharma US, Inc.12$213
Ascendis Pharma Endocrinology Inc8$198
Valeritas, Inc.16$184
Tandem Diabetes Care, Inc.7$141
Cequr Corporation3$138
Almatica Pharma LLC5$125
Averitas Pharma Inc.5$117
Halozyme Inc6$108
IBSA Pharma Inc.6$106
Intuitive Surgical1$99
Soleno Therapeutics, Inc.3$85
Madrigal Pharmaceuticals4$85
Vivus LLC8$84
Intuity Medical Inc4$77
Takeda Pharmaceuticals U.S.A., Inc.2$59
Novartis2$51
Ascensia Diabetes Care US Inc.3$50
Companion Medical, Inc.3$45
Neurocrine Biosciences, Inc.2$45
Shire North American Group Inc3$45
Eton Pharmaceuticals, Inc.1$40
Nevro Corp.2$40
Ipsen Biopharmaceuticals, Inc2$39
Verity Pharmaceuticals Inc.2$35
Johnson & Johnson2$28
Ultragenyx Pharmaceutical Inc.1$24
Acella Pharmaceuticals, LLC1$22
Gilead1$20
Tolmar, Inc.1$19
Sequel Med Tech, LLC1$19
Echosens North America, Inc.1$18
Amphastar Pharmaceuticals, Inc.1$17
Pfizer1$14
Globus Medical1$14
Alfasigma USA, Inc.1$14
Amarin Pharma, Inc.1$13
Vistapharm, Inc.1$13

How this compares

$110,638 in reported general payments places this provider in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona →

Medicare billing

Part B allowed, 2024
$192,523
Medicare patients
591
Services billed
10,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Mesa

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →